PP / EVIDENCE 001 REVIEWED AUGUST 15, 2026
Peptide research,
without the mythology.
Discovery history, animal models, human studies, FDA status, and the real research promise of every peptide or related compound in the Peptiva Prime evidence registry.
INDEX / A–Z PRIMARY SOURCES + REGISTRIES
The evidence index.
Ace-031
A single primary-source discovery event and individual discoverer for Ace-031 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Adamax
A single primary-source discovery event and individual discoverer for Adamax were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Adipotide
The adipose-targeting peptidomimetic later called adipotide was reported by Barnhart and colleagues in 2011 after vascular-targeting work from the Kolonin, Pasqualini, and Arap research program.
AHK-CU
A single primary-source discovery event and individual discoverer for AHK-CU were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
AICAR
A single primary-source discovery event and individual discoverer for AICAR were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Alprostadil
A single primary-source discovery event and individual discoverer for Alprostadil were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
AOD-9604
A single primary-source discovery event and individual discoverer for AOD-9604 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
ARA-290 (cibinetide)
A single primary-source discovery event and individual discoverer for ARA-290 (cibinetide) were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
B7-33
B7-33 was described by Hossain and colleagues in the Bathgate research group in 2016 as a single-chain relaxin-family peptide agonist designed to bias RXFP1 signaling.
Bacteriostatic Water
A single primary-source discovery event and individual discoverer for Bacteriostatic Water were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Botulinum Toxin
Émile van Ermengem identified the bacterium responsible for botulism in the 1890s; modern botulinum-toxin medicines emerged through later purification, subtype characterization, and clinical development. The historical discovery does not make an unverified toxin product equivalent to an approved biologic.
BPC 5mg + TB 5mg
A single primary-source discovery event and individual discoverer for BPC 5mg + TB 5mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
BPC 10mg + TB 10mg
A single primary-source discovery event and individual discoverer for BPC 10mg + TB 10mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
BPC 157 10mg+GHK-CU 50mg+TB500 10mg
A single primary-source discovery event and individual discoverer for BPC 157 10mg+GHK-CU 50mg+TB500 10mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
BPC-157
A single primary-source discovery event and individual discoverer for BPC-157 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
BPC157 10mg+GHK-CU 50mg+TB500 10mg+KPV 10mg
A single primary-source discovery event and individual discoverer for BPC157 10mg+GHK-CU 50mg+TB500 10mg+KPV 10mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Bronchogen
A single primary-source discovery event and individual discoverer for Bronchogen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
cagrilintide
A single primary-source discovery event and individual discoverer for cagrilintide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
cagrilintide 5mg+Semaglutide 5mg
A single primary-source discovery event and individual discoverer for cagrilintide 5mg+Semaglutide 5mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Cardiogen
A single primary-source discovery event and individual discoverer for Cardiogen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Cartalax
A single primary-source discovery event and individual discoverer for Cartalax were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
cerebrolysin
A single primary-source discovery event and individual discoverer for cerebrolysin were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Chonluten
A single primary-source discovery event and individual discoverer for Chonluten were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
CJC-1295 With DAC
CJC-1295, a long-acting growth-hormone-releasing-hormone analog linked to a drug-affinity complex, was in early human development by the mid-2000s; Teichman and colleagues published a randomized human study in 2006.
CJC-1295 without DAC
The name ‘CJC-1295 without DAC’ is used commercially for shorter-acting modified GRF analogs, but it does not describe the same molecular design as DAC-linked CJC-1295. A single, definitive discovery paper for this catalog naming convention was not established.
CJC-1295 without DAC 5mg + IPA 5mg
A single primary-source discovery event and individual discoverer for CJC-1295 without DAC 5mg + IPA 5mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
CJC-1295 without DAC 10mg + IPA 10mg
A single primary-source discovery event and individual discoverer for CJC-1295 without DAC 10mg + IPA 10mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Cortagen
A single primary-source discovery event and individual discoverer for Cortagen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Crystagen
A single primary-source discovery event and individual discoverer for Crystagen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Dermorphin
A single primary-source discovery event and individual discoverer for Dermorphin were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
DSIP
Delta sleep-inducing peptide was characterized by Schoenenberger and Monnier in the 1970s following sleep-factor experiments in rabbits; the peptide was reported in the literature by 1977.
Epithalon
Epitalon (often spelled Epithalon) was developed in the Khavinson research program as a synthetic tetrapeptide related to peptide fractions studied from the pineal gland. English-language papers appeared by the early 2000s.
EPO
A single primary-source discovery event and individual discoverer for EPO were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
GHK
GHK was identified in human plasma during Loren Pickart’s work on age-dependent effects of plasma on liver-cell growth in the 1970s. Copper-binding GHK-Cu was characterized in subsequent work.
GHK-CU
GHK was identified by Loren Pickart in human plasma in the 1970s; subsequent studies characterized its high-affinity copper complex, GHK-Cu.
GHRP-2 Acetate
A single primary-source discovery event and individual discoverer for GHRP-2 Acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
GHRP-6 Acetate
A single primary-source discovery event and individual discoverer for GHRP-6 Acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Glutathione
A single primary-source discovery event and individual discoverer for Glutathione were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Gonadorelin Acetate
The hypothalamic decapeptide GnRH was isolated, sequenced, and synthesized independently by groups led by Andrew Schally and Roger Guillemin around 1971. Gonadorelin is synthetic GnRH.
HCG
A single primary-source discovery event and individual discoverer for HCG were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Hexarelin Acetate
A single primary-source discovery event and individual discoverer for Hexarelin Acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
HGH Fragment 176-191
A single primary-source discovery event and individual discoverer for HGH Fragment 176-191 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
HMG
A single primary-source discovery event and individual discoverer for HMG were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Humanin
Humanin was identified by Hashimoto and colleagues in 2001 through functional screening for genes that protected neuronal cells from Alzheimer-disease-related toxicity.
hyaluronic acid
Karl Meyer and John Palmer isolated hyaluronic acid from bovine vitreous humor in 1934. It is a polysaccharide, not a peptide.
IGF-1LR3
A single primary-source discovery event and individual discoverer for IGF-1LR3 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Ipamorelin
Ipamorelin was described by Raun and colleagues in 1998 as a selective growth-hormone secretagogue in preclinical pharmacology studies.
KissPeptin-10
A single primary-source discovery event and individual discoverer for KissPeptin-10 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
KPV
A single primary-source discovery event and individual discoverer for KPV were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Lemon Bottle
A single primary-source discovery event and individual discoverer for Lemon Bottle were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Liraglutide
A single primary-source discovery event and individual discoverer for Liraglutide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Livagen
A single primary-source discovery event and individual discoverer for Livagen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
LL-37
The human cathelicidin precursor hCAP18 and its active peptide LL-37 were characterized by the Agerberth and Gudmundsson research groups in the mid-1990s.
Matrixyl
A single primary-source discovery event and individual discoverer for Matrixyl were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Mazdutide
A single primary-source discovery event and individual discoverer for Mazdutide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Melanotan I / afamelanotide
A single primary-source discovery event and individual discoverer for Melanotan I / afamelanotide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Melanotan II acetate
A single primary-source discovery event and individual discoverer for Melanotan II acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
MGF
Mechano growth factor was described by Geoffrey Goldspink’s group as a locally expressed, mechanically responsive IGF-1 splice variant; Yang and Goldspink reported the human splice form in 2002.
MOTS-c
MOTS-c was identified by Lee and colleagues in 2015 as a mitochondrial-DNA-encoded peptide with metabolic effects in cell and mouse models.
N-Acetyl Epitalon Amidate
A single primary-source discovery event and individual discoverer for N-Acetyl Epitalon Amidate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
NA Selank amidate
A single primary-source discovery event and individual discoverer for NA Selank amidate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
NA Semax amidate
A single primary-source discovery event and individual discoverer for NA Semax amidate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
NAD+
A single primary-source discovery event and individual discoverer for NAD+ were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Ovagen
A single primary-source discovery event and individual discoverer for Ovagen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Oxytocin Acetate
Henry Dale reported uterotonic activity from posterior-pituitary extracts in 1906. Vincent du Vigneaud’s group determined oxytocin’s structure and completed its synthesis in the early 1950s.
P21(Adamantane-free)
A single primary-source discovery event and individual discoverer for P21(Adamantane-free) were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
P21(with Adamantane)
A single primary-source discovery event and individual discoverer for P21(with Adamantane) were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Pancragen
A single primary-source discovery event and individual discoverer for Pancragen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
PE 22-28
A single primary-source discovery event and individual discoverer for PE 22-28 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
PEG MGF
A single primary-source discovery event and individual discoverer for PEG MGF were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Pinealon
A single primary-source discovery event and individual discoverer for Pinealon were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Pnc 27
A single primary-source discovery event and individual discoverer for Pnc 27 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Prostamax
A single primary-source discovery event and individual discoverer for Prostamax were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
PT-141 / bremelanotide
A single primary-source discovery event and individual discoverer for PT-141 / bremelanotide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
PTD-DBM
A single primary-source discovery event and individual discoverer for PTD-DBM were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Retatrutide
A single primary-source discovery event and individual discoverer for Retatrutide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Retatrutide 5mg+cagrilintide 5mg
A single primary-source discovery event and individual discoverer for Retatrutide 5mg+cagrilintide 5mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Selank
A single primary-source discovery event and individual discoverer for Selank were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Semaglutide
Semaglutide was designed within Novo Nordisk’s GLP-1 analog program. Lau and colleagues published its discovery and preclinical development in 2015.
Semax
A single primary-source discovery event and individual discoverer for Semax were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Semax 10mg+Selank 10mg
A single primary-source discovery event and individual discoverer for Semax 10mg+Selank 10mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Sermorelin Acetate
A single primary-source discovery event and individual discoverer for Sermorelin Acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
snap-8
A single primary-source discovery event and individual discoverer for snap-8 were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Somatropin (hGH 191AA)
A single primary-source discovery event and individual discoverer for Somatropin (hGH 191AA) were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
SS-31 / elamipretide
SS-31 belongs to the Szeto–Schiller class of cell-permeable, mitochondria-targeting peptides developed through work led by Hazel Szeto and Peter Schiller in the early 2000s. The drug name is elamipretide.
Survodutide
A single primary-source discovery event and individual discoverer for Survodutide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
TB-500 fragment
A single primary-source discovery event and individual discoverer for TB-500 fragment were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Teriparatide
A single primary-source discovery event and individual discoverer for Teriparatide were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Tesamorelin
A single primary-source discovery event and individual discoverer for Tesamorelin were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Tesamorelin 12mg+Ipamorelin 6mg
A single primary-source discovery event and individual discoverer for Tesamorelin 12mg+Ipamorelin 6mg were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Testagen
A single primary-source discovery event and individual discoverer for Testagen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Thymalin
A single primary-source discovery event and individual discoverer for Thymalin were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Thymosin Alpha-1
Thymosin alpha-1 was isolated from thymosin fraction 5 and sequenced by Allan Goldstein and colleagues in the 1970s; a primary report appeared in 1977.
Thymosin beta-4 acetate
A single primary-source discovery event and individual discoverer for Thymosin beta-4 acetate were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Tirzepatide
Tirzepatide was developed by Eli Lilly as a single peptide with dual GIP- and GLP-1-receptor agonism. Coskun and colleagues reported its preclinical and early clinical profile in 2018.
Triptorelin
A single primary-source discovery event and individual discoverer for Triptorelin were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Vasoactive intestinal peptide (VIP)
Sami Said and Viktor Mutt isolated vasoactive intestinal peptide from porcine intestine and reported the peptide in 1970.
Vesugen
A single primary-source discovery event and individual discoverer for Vesugen were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.
Vilon
A single primary-source discovery event and individual discoverer for Vilon were not established in this review. This name may represent a later analog, fragment, salt, proprietary formulation, blend, or catalog convention rather than one discrete discovery. The linked literature map is the starting point for a deeper historical review.